The global antacids market was valued at USD 6.6 billion in 2022 and is anticipated to grow to USD 8.79 billion by 2030, representing a CAGR of 3.7% from 2023 to 2030. One of the primary factors expected to drive market growth during the forecast period is the shift in dietary habits.
The rising incidence of gastroesophageal reflux disease (GERD), peptic ulcers, and other digestive disorders that lead to issues like acidity, digestive problems, and heartburn is also predicted to propel market demand. A study published by the National Institutes of Health (NIH) in 2022 reported that 783.95 million individuals were diagnosed with GERD globally in 2019. From 1990 to 2019, the total number of years lived with disability (YLD) rose by 77.19%, the total number of prevalent cases increased by 77.53%, and the total number of incident cases grew by 74.79%.
Moreover, increasing awareness about GERD is expected to further stimulate market growth. An article from the International Foundation for Gastrointestinal Disorders highlighted that the 23rd Annual GERD Awareness Week took place in November 2022, offering information and support for those affected. Additionally, the International Foundation for Functional Gastrointestinal Disorders (IFFGD) encourages patients experiencing GERD-related symptoms to seek advice from their healthcare providers.
Key Market Trends & Insights
• Regionally, North America leads the antacid market, holding a revenue share of 44.0% in 2022. This dominance is due to a well-established healthcare system and infrastructure, high disposable incomes, and a growing elderly population. Additionally, a rise in digestive disorders is expected to contribute to this trend.
• The Asia Pacific region is anticipated to experience the highest compound annual growth rate (CAGR) of 5.4% during the forecast period, driven by significant unmet clinical needs, the availability of effective treatment options, increasing disposable incomes, and heightened consumer awareness regarding these products.
• By end-use, the market is divided into hospital pharmacy, retail pharmacy, and online pharmacy. The retail pharmacy segment accounted for the largest revenue share at 41.5% in 2022, attributed to ease of access, convenience, and the proximity of pharmacy locations. Apollo Pharmacy stands as India’s largest pharmacy chain, boasting over 4,200 stores nationwide in 2022.
• In terms of type, the market is categorized into tablets, liquids, and others. The tablets segment led the market in 2022, with the availability of chewable tablets in various flavors enhancing patient adherence. Tablets also offer precise dosage compared to other forms and are convenient to store.
Order a free sample PDF of the Antacids Market Intelligence Study, published by Grand View Research.
Market Size & Forecast
• 2022 Market Size: USD 6.6 Billion
• 2030 Projected Market Size: USD 8.79 Billion
• CAGR (2023-2030): 3.7%
• North America: Largest market in 2022
• Asia Pacific: Fastest growing market
Key Companies & Market Share Insights
The market features competition among numerous multinational corporations and smaller businesses all vying for a larger share. Key strategies employed by major players include launching new products, expanding geographically, and forming joint ventures.
For instance, in February 2022, GlaxoSmithKline plc (GSK) announced its plan to demerge and list Haleon, a consumer health company. Haleon is set to manage various brands, including the antacids TUMS and ENO. This strategic move aims to help GSK establish a focused global consumer healthcare business through the introduction of Haleon. Haleon's strategy is built upon four main components: portfolio growth and penetration, capitalizing on growth opportunities, robust execution, financial discipline, and responsible business operations.
Furthermore, in June 2022, Wonderbelly, a startup based in Austin, introduced its over-the-counter (OTC) chewable antacid tablets, also named Wonderbelly. These tablets come in flavors like strawberry milkshake, watermelon mint, and fruity cereal. The product is notable for being non-GMO, vegan, and free from talc, synthetic sweeteners, dyes, common allergens, dairy, parabens, gluten, artificial flavors, and preservatives.
Key Players
• GlaxoSmithKline plc
• Bayer AG
• Boehringer Ingelheim International GmbH
• Dr. Reddy’s Laboratories Ltd.
• Sanofi
• Reckitt Benckiser Group plc
• Sun Pharmaceuticals Ltd.
• Takeda Pharmaceutical Company Limited
• Pfizer Inc.
• Procter & Gamble
Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.
Conclusion
Key growth drivers of global antacids market are changing dietary habits and the rising prevalence of gastroesophageal reflux disease (GERD), peptic ulcers, and other digestive disorders that cause acidity and heartburn. A 2022 NIH study noted that 783.95 million people were diagnosed with GERD globally in 2019, with significant increases in disability years and prevalent cases from 1990 to 2019. Additionally, heightened awareness about GERD, highlighted during the 23rd Annual GERD Awareness Week in November 2022, is expected to further boost market growth, encouraging patients to consult healthcare providers for symptoms.